Nonalcoholic Fatty Liver Disease
Clinicians must be aware of the overlap between nonalcoholic fatty liver disease and nonalcoholic steatohepatitis and other metabolic disorders.
Treatment with saroglitazar was linked to sonographic improvement in fatty liver.
For obese patients with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is associated with an unfavorable metabolic profile.
Exposure to low doses of hormone-disrupting chemicals may alter the liver genome and function, thereby increasing susceptibility to obesity.
Patients with type 1 diabetes may be less likely to develop fatty liver disease.
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Normalized HbA1c Levels Facilitate Improved Neuropathy Outcomes in T2D
- Hypertensive Disorders in Pregnancy, Postpartum BMI Linked to T2D Risk
- Sleep Quality, Duration Affect Risk for Falls and Fractures in Older Women
- Physician Burnout Linked to Stress in Using Health Information Technology
- Type 2 Diabetes Linked to Colorectal Cancer Risk in Men
- Urinary Incontinence Drug May Reduce Frequency of Hot Flashes